Polymer Microparticles Prolong Delivery of the 15-PGDH Inhibitor SW033291

Alan B. Dogan, Nathan A. Rohner, Julianne N.P. Smith, Jessica A. Kilgore, Noelle S. Williams, Sanford D. Markowitz, Horst A. von Recum, Amar B. Desai

Research output: Contribution to journalArticlepeer-review

Abstract

As the prevalence of age-related fibrotic diseases continues to increase, novel antifibrotic therapies are emerging to address clinical needs. However, many novel therapeutics for managing chronic fibrosis are small-molecule drugs that require frequent dosing to attain effective concentrations. Although bolus parenteral administrations have become standard clinical practice, an extended delivery platform would achieve steady-state concentrations over a longer time period with fewer administrations. This study lays the foundation for the development of a sustained release platform for the delivery of (+)SW033291, a potent, small-molecule inhibitor of the 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme, which has previously demonstrated efficacy in a murine model of pulmonary fibrosis. Herein, we leverage fine-tuned cyclodextrin microparticles—specifically, β-CD microparticles (β-CD MPs)—to extend the delivery of the 15-PGDH inhibitor, (+)SW033291, to over one week.

Original languageEnglish (US)
Article number85
JournalPharmaceutics
Volume14
Issue number1
DOIs
StatePublished - Jan 2022
Externally publishedYes

Keywords

  • 15-PGDH
  • Affinity
  • Cyclodextrin
  • Fibrosis
  • SW033291

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Polymer Microparticles Prolong Delivery of the 15-PGDH Inhibitor SW033291'. Together they form a unique fingerprint.

Cite this